Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem chłoniaka z dużych komórek B (DLBCL) na podstawie badania histologicznego
- •Choroba nawróciła lub nie reaguje na leczenie po co najmniej dwóch poprzednich seriach chemioterapii
- •Wcześniejsze leczenie musiało zawierać antracyklin i terapię anty-CD20
- •Obecność mierzalnych zmian nowotworu (węzły chłonne > 1,5 cm lub inne zmiany > 1,0 cm)
- •Chęć i zdolność do pobytu w szpitalu i uczestnictwa we wszystkich badaniach
- •Zgoda na uczestnictwo w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 3, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tianjin Medical University Cancer Insititute & Hospital
Tianjin, China
Trial contact
Huilai Zhang
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/4/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.